Evidence map›Paper›PMID 36103894›Full record

ArticleCell2022

mTOR-regulated mitochondrial metabolism limits mycobacterium-induced cytotoxicity.

Antonio J Pagán, Lauren J Lee, Joy Edwards-Hicks, Cecilia B Moens, David M Tobin, Elisabeth M Busch-Nentwich, Erika L Pearce, Lalita Ramakrishnan

Open access · hybridAbstract read
In one paragraph

Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Control of antigen presentation on MHC-I by a bacterial secretion system.bioRxiv : the preprint server for biology · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. A granulin-positive macrophage subtype in mycobacterial granulomas alleviates tissue damage by limiting excessive inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Antonio J PagánMolecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge CB2 0AW, UK; MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK; Department of Microbiology, University of Washington, Seattle, WA 98195, USA. Electronic address: apagan@mrc-lmb.cam.ac.uk.
Lauren J LeeMolecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge CB2 0AW, UK; MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Joy Edwards-HicksMax Planck Institute of Immunobiology and Epigenetics, Freiburg im Breisgau, Germany.
Cecilia B MoensDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
David M TobinDepartment of Microbiology, University of Washington, Seattle, WA 98195, USA.
Elisabeth M Busch-NentwichMolecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge CB2 0AW, UK.
Erika L PearceMax Planck Institute of Immunobiology and Epigenetics, Freiburg im Breisgau, Germany.
Lalita RamakrishnanMolecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge CB2 0AW, UK; MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK; Department of Microbiology, University of Washington, Seattle, WA 98195, USA. Electronic address: lalitar@mrc-lmb.cam.ac.uk.
MRC Laboratory of Molecular Biology · GBMax Planck Institute of Immunobiology and Epigenetics · DEFred Hutch Cancer Center · USUniversity of Cambridge · GBUniversity of Washington · US

Funding

Host-Responses to Mycobacterium Infection in ZebrafishR37AI054503 · NIAID · UNIVERSITY OF WASHINGTON · PI RAMAKRISHNAN, LALITA · 2012 to 2021
$3.1M
INTERDISCIPLINARY PROGRAM IN BACTERIAL PATHOGENESIST32AI055396 · NIAID · UNIVERSITY OF WASHINGTON · PI FANG, FERRIC C · 2003 to 2019
$2.8M
Linking the behavior of individual host cells to their transcriptional signaturesDP1MH099901 · NIMH · UNIVERSITY OF WASHINGTON · PI RAMAKRISHNAN, LALITA · 2012 to 2014
$2.3M
NIAID NIH HHS R37 AI054503NIAID NIH HHS T32 AI055396NIMH NIH HHS DP1 MH099901Wellcome Trust 223103/Z/21/Z
6 · The paper itself

Abstract

Necrosis of macrophages in the granuloma, the hallmark immunological structure of tuberculosis, is a major pathogenic event that increases host susceptibility. Through a zebrafish forward genetic screen, we identified the mTOR kinase, a master regulator of metabolism, as an early host resistance factor in tuberculosis. We found that mTOR complex 1 protects macrophages from mycobacterium-induced death by enabling infection-induced increases in mitochondrial energy metabolism fueled by glycolysis. These metabolic adaptations are required to prevent mitochondrial damage and death caused by the secreted mycobacterial virulence determinant ESAT-6. Thus, the host can effectively counter this early critical mycobacterial virulence mechanism simply by regulating energy metabolism, thereby allowing pathogen-specific immune mechanisms time to develop. Our findings may explain why Mycobacterium tuberculosis, albeit humanity's most lethal pathogen, is successful in only a minority of infected individuals.

Indexed as

Mycobacterium marinumMycobacterium tuberculosisTuberculosisAnimalsTOR Serine-Threonine KinasesZebrafishTOR Serine-Threonine KinasesESAT-6 mitotoxicitygranuloma necrosismacrophage deathmitochondrial metabolismmTORMycobacterium marinumMycobacterium tuberculosisoxidative phosphorylationtuberculosiszebrafish TB model

Identifiers

PMID36103894
PMCPMC9596383
OpenAlexW4295907787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.